Get started
Work

1088MO A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up

Year: 2023
Type: article
DOI: 10.1016/j.annonc.2023.09.2222
Authors: N. Gross, D.M. Miller, N.I. Khushalani, V. Divi, E. Ruiz, E.J. Lipson, F. Meier, Y.B. Su, P.L. Swiecicki, J.L. Atlas, J.L. Geiger, A. Hauschild, J.H. Choe, B.G.M. Hughes, S-Y. Yoo, M.D. Mathias, H. Han, M.G. Fury, D. Rischin
Institutions: The University of Texas MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, Moffitt Cancer Center, Stanford Medicine, Stanford University, Brigham and Women's Hospital, Harvard University, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University Hospital Carl Gustav Carus, Nationales Centrum für Tumorerkrankungen Dresden, Nebraska Cancer Specialists, University of Michigan, U-M Rogel Cancer Center, Carolinas Healthcare System, Levine Cancer Institute, Cleveland Clinic, University Hospital Schleswig-Holstein, Duke Cancer Institute, The University of Queensland, Royal Brisbane and Women's Hospital, Regeneron (United States), The University of Melbourne, Peter MacCallum Cancer Centre
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4387811079
FWCI:
Cites:
Cited by: 1
Related to: 10